Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effects of Sedatives on Tobacco Use Disorder Version 2
NCT05505630Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine, midazolam and dexmedetomidine in Tobacco Use Disorder (TUD) (12 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Difference in craving between drug and placebo, Difference in tobacco withdrawal symptoms and 2 more. Started Jan 2023; status: completed.
02
Drugs
ketaminemidazolamdexmedetomidine
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05505630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505630.